Effexor (venlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) prescribed for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. By affecting both serotonin and norepinephrine, it offers a dual mechanism that can be particularly effective when SSRIs alone are insufficient.
The most frequently reported Effexor side effects include nausea (especially during the first 1-2 weeks), headaches, dizziness, drowsiness or insomnia, dry mouth, increased sweating (often excessive), decreased appetite, constipation, and sexual dysfunction. Nausea is typically the most prominent early complaint and can be minimized by taking Effexor with food and starting at a low dose. The extended-release formulation (Effexor XR) generally produces fewer peak-related side effects than immediate-release.
Unlike SSRIs, Effexor can increase blood pressure, particularly at higher doses (225mg+). This norepinephrine-mediated effect requires monitoring. Your psychiatrist should check your blood pressure at baseline and periodically during treatment. The risk is dose-dependent and typically manageable, but adults with pre-existing hypertension need careful monitoring.
Effexor is widely regarded as one of the most challenging psychiatric medications to discontinue. Its short half-life (approximately 5 hours for immediate-release, 11 hours for XR) means discontinuation symptoms can emerge within hours of a missed dose. Symptoms include severe dizziness and vertigo, electric shock sensations ("brain zaps"), nausea and vomiting, irritability and agitation, vivid nightmares, flu-like symptoms, and rebound anxiety or depression. Tapering must be done very gradually, often over months rather than weeks, with dose reductions of 25% or less at each step. If you miss a dose and experience symptoms, take it as soon as possible and discuss a more gradual taper with your psychiatrist if you plan to discontinue.
Effexor may be a good choice when SSRIs like sertraline or Lexapro haven't provided adequate relief, when both depression and anxiety are present, when fatigue and low energy are prominent symptoms (norepinephrine effects can be activating), or when chronic pain co-occurs with depression or anxiety (SNRIs have demonstrated pain-relieving properties). A comprehensive psychiatric evaluation helps determine whether an SNRI like Effexor is the right fit for your symptom profile.
Effexor is generally weight-neutral to slightly appetite-suppressing in the short term. Some adults experience modest weight gain with long-term use. Overall, it causes less weight gain than medications like mirtazapine, paroxetine, or atypical antipsychotics, making it a reasonable choice when weight concerns are a priority.
Effexor inhibits reuptake of both serotonin and norepinephrine, while SSRIs only affect serotonin. At lower doses (75-150mg), Effexor functions primarily as an SSRI. At higher doses (150-375mg), its norepinephrine effects become more prominent, providing the dual mechanism that distinguishes it. This dose-dependent pharmacology means your prescriber can effectively tailor the mechanism by adjusting the dose.
Yes. Switching from an SSRI to Effexor is a common clinical move when the SSRI provides partial but insufficient relief. Your psychiatrist will typically taper the SSRI while gradually introducing Effexor, sometimes with a brief overlap period. Cross-tapering protocols vary based on which specific SSRI you're switching from.
Another SSRI option is citalopram (Celexa), which is highly selective for serotonin but has a dose ceiling due to cardiac concerns.
Sometimes depression or trauma manifests not as sadness but as emotional numbness — an inability to feel anything at all.
This content is for informational purposes only and should not replace professional medical advice, diagnosis, or treatment. If you have questions about Effexor, schedule an appointment with Elevate Psychiatry. We serve adults 18 and older through our Miami offices in Coconut Grove and Doral, as well as virtually throughout Florida.
